Skip to content

Released Mar 23, 2026, after the close

10-K filed Mar 23, 2026, 82 days after period end · 0001193125-26-119873

Q4 2025 · 10-K

derived · Computed from the longer spans the company filed.

Revenue$11.65Mderived−21.4% vs Q4 2024+20.2% vs Q3 2025
Net Income-$46.76MderivedN/M vs Q4 2024N/M vs Q3 2025
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived-$38,049,000N/M
Operating Cash Flowderived-$26,435,000N/M
Margins · derived
Operating margin-326.7%+114.0 pt vs Q4 2024
Net margin-401.5%+87.7 pt vs Q4 2024

What the release said

The release

Same quarter

MetricQ4 2025derived from reported figuresQ4 2024derived from reported figuresQ4 2023derived from reported figuresQ4 2022derived from reported figures
Revenue$11.65M$14.81M$113.72M$8.63M
Net Income-$46.76M-$72.44M$31.07M-$34.59M

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Sutro Biopharma, Inc. · CIK 1382101 · Engraved from SEC EDGAR